NCT03725670View on ClinicalTrials.gov

Direct Lentiviral Injection Gene Therapy for MLD

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2030

Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
GENETIC

Intrathecal and intravenous LV gene therapy

Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 transduction units/ml which carry a normal ARSA gene

Trial Locations (1)

518000

RECRUITING

Lung-Ji Chang, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT03725670 - Direct Lentiviral Injection Gene Therapy for MLD | Biotech Hunter | Biotech Hunter